LTR Pharma (ASX:LTP) Cash Payments: A$-9.20 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:LTP LTR Pharma Ltd ASX:LTP
12 GF Score
Price A$0.49
View Full Analysis

What is LTR Pharma Cash Payments?

LTR Pharma ASX:LTP -1.02% 12 Cash Payments is A$-9.20 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 12/100.

LTR Pharma's Cash Payments for the six months ended in Dec. 2025 was A$-5.50 Mil.

LTR Pharma's Cash Payments for the trailing twelve months (TTM) ended in Dec. 2025 was A$-9.20 Mil.

LTR Pharma Cash Payments Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Cash Payments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Cash Payments Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Cash Payments
-0.03 -0.58 -1.54 -5.14 -6.54

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Payments Get a 7-Day Free Trial -2.21 -2.94 -2.84 -3.70 -5.50
ASX:LTP
12GF Score
LTR Pharma Ltd ASX:LTP
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Cash Payments Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Payments represents cash flow paid from operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for non-financial companies:
Payments to Suppliers for Goods and Services
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Cash Payments for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-9.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Payments →
What does a Cash Payments of A$-9.20 Mil mean?
LTR Pharma (ASX:LTP) has a Cash Payments of A$-9.20 Mil as of Dec. 2025. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for LTR Pharma and its competitors.
Is LTR Pharma's Cash Payments too high?
LTR Pharma's current Cash Payments is A$-9.20 Mil. Overall, LTR Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Cash Payments compare to VRTX and REGN?
LTR Pharma's Cash Payments of A$-9.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Payments for a Biotechnology company?
A good Cash Payments depends on the Biotechnology industry context. However, Cash Payments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Payments mean?
A high Cash Payments can signal that a stock is expensive relative to its fundamentals. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for LTR Pharma and its competitors. LTR Pharma's current Cash Payments is A$-9.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Cash Payments of A$-9.20 Mil. The current Cash Payments is A$-9.20 Mil. LTR Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Payments calculated?
Cash Payments is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Cash Payments is A$-9.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
12GF Score

Get the complete analysis for ASX:LTP

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.49
Price